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Objective: We investigated the effects of tocilizumab (TCZ) on joint tissue remodeling in patients with
moderate to severely active RA by measuring tissue-speciﬁc biomarker.
Methods: The LITHE biomarker study (n ¼ 740) was a phase III study of 4- and 8-mg/kg TCZ in
combination with MTX. Early response was evaluated at week 16 as 720% improvement in swollen/
tender joint counts; and ACR50 was evaluated at week 52. Biomarkers (tissue inﬂammation: C3M, CRPM,
and VICM; cartilage degradation: C2M; and bone turnover: CTx and osteocalcin) were tested in serum
from baseline, week 4, 16, 24, and 52, and dose-dependent effect was investigated. Patients were divided
into the following three groups: early non-responders (ENR), ACR50 responders, and non-responders;
their biomarker proﬁles were compared.
Results: At week 52, CRP was inhibited to 4% and 40% of baseline by TCZ8 and TCZ4, respectively. CRPM
(63%), C2M (84%), C3M (69%), and VICM (42%) were signiﬁcantly (p o 0.05) reduced by TCZ8, but not by
TCZ4. MMP3 and osteocalcin changed to o58% and 4111%, respectively, in response to TCZ. CTx was not
changed signiﬁcantly. ENRs had signiﬁcantly less inhibition of CRPM (p o 0.05), C2M (p o 0.01), and
C3M (p o 0.01) compared to early responders. There was a signiﬁcant difference in the C2M, C3M, and
CRPM proﬁles of the ENRs, non-responders, and responders. ACR50 responders had signiﬁcantly
inhibited levels (p o 0.001), irrespective of dose.
Conclusions: TCZ8 strongly inhibited the biomarkers of joint tissue remodeling suggesting that TCZ actively
suppresses key pathobiological processes at the site of inﬂammation in RA patients. The differences in
biomarkers' proﬁles of responders and non-responders indicate that speciﬁc responder proﬁles exist.
& 2014 The Authors. Published by Elsevier HS Journals, Inc. Open access under CC BY-NC-SA license. HS Journals, Inc.
tology; ANOVA, analysis of
rve; BMI, body mass index;
telopeptide of type I
ivity score; DMARD, disease-
immunosorbent assay; ESR,
gue against Rheumatism; JSN,
otrexate; OC, osteocalcin; RA,
ndard error of the mean; sIL-
onated by Roche–Genentech.
Danish Research foundation.
oundation had no role in the
ved the ﬁnal manuscript.
ay-Jensen).
Open access under CIntroduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease that
is characterized by poly-articular inﬂammation associated with
synovitis, osteitis, and periarticular osteopenia, often associated
with loss of cartilage and erosion of subchondral bone. These
features commonly lead to progressive joint damage, impaired
function, and disability [1,2]. The challenges in the RA ﬁeld have
shifted from ﬁnding efﬁcacious treatment options to identiﬁcation
of those patients who will beneﬁt the most from treatment. It may
therefore be critical to identify biomarkers or a panel of bio-
markers that are diagnostic and predictive.
In RA, it is the persistent burden of pro-inﬂammatory cytokines,
such as interleukins (e.g., IL-1, IL-6, and IL-17) and tumor necrosis
factor alpha (TNFα), secreted by monocytes, T, and B cells, which
drives disease progression. This leads to activation of the several
signaling cascades, such as janus kinases (JAK), spleen tyrosin kinase
(SYK), and mitogen-activated protein (MAP) kinases, ultimately
resulting in the secretion of proteolytical enzymes, such as matrix
metalloproteinases (MMPs), which are the main mediators of tissueC BY-NC-SA license. 
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involved in the process and consequent signaling pathways may be
large, the common end product is tissue destruction by cleavage of
joint-speciﬁc proteins mediated by the increase in the proteases [4].
Thus measurement of end products of tissue destruction may provide
more value than measurement of individual proteases and cytokines.
The elevated proteolytic activity results in the release of
protein-speciﬁc tissue fragments and neo-epitopes, which have
been investigated as biomarkers of joint disease [5]. Validated
examples of neo-epitope biomarkers are those released following
cleavage of type II collagen by MMPs, which reﬂect cartilage
degradation. Among these biomarkers are serum MMP-degraded
type II collagen (C2M) [6], urinary C-terminal telopeptide (CTX-II)
[7–9], and the one-quarter fragment (C2C, TIINE) [10]. Other
connective tissues, such as the synovium, are modulated by
proteases, and neo-epitope biomarkers of synovium have also
been identiﬁed. One such serum marker is C3M, which measures
speciﬁc fragments of type III collagen and has recently been
associated with inﬂammation-driven tissue turnover and ﬁbrosis
[11,12]. Measurement of serum CRP, an acute-phase reactant
produced in the liver, is considered an excellent tool for diagnosing
acute inﬂammatory diseases, but has little prognostic or predictive
value [13]. Recently, a newly developed CRP measure was
described. CRPM (i.e., CRP degraded by MMP) can be measured
in serum to quantify CRP fragments released from the inﬂamed
tissue, after CRP has been synthesized in the liver and deposited in
the joint and degraded in the joint by the proteolytic burden [14].
Interleukin-6 (IL-6) is a pleiotropic cytokine involved in several
pathways of inﬂammation and in bone and cartilage metabolism
in RA [15]. Tocilizumab (TCZ) is a humanized anti-IL-6 receptor
(IL-6R) monoclonal antibody. The effects of TCZ on bone turnover
markers have been examined in several other RA clinical studies,
including RADIATE [16] and OPTION [17]. These studies showed
that both 4- and 8-mg/kg TCZ inhibited bone resorption signiﬁ-
cantly, whereas bone formation, measured by serum osteocalcin,
was induced only by 8 mg/kg. This indicates that there are marked
differences between the two approved doses (in US and EU,
respectively). Analysis of structural changes by radiography
showed that the two doses were equally protective against joint
destruction [18], which highlights the need for further investiga-
tion of differences between doses.
This report summarizes the efﬁcacy of exploratory biomarkers
measured in the pivotal phase III called LITHE [18,19]. The LITHE
study was designed to evaluate the effects of TCZ, 4 mg/kg þ
methotrexate (MTX) or 8 mg/kg þ MTX, and placebo þ MTX in
RA patients with moderate to severe disease and non-responsive to
DMARD. The aim of the current serological biomarker analysis was
to investigate the effect of the two approved doses of TCZ, 4 mg/kg
and 8 mg/kg compared to placebo, on the release of speciﬁc and
descriptive biomarkers reﬂecting joint deterioration and inﬂamma-
tion. The biomarkers were C2M (a measure of cartilage degradation),
C3M (indicating synovial inﬂammation), MMP3, total CRP, CRPM
(tissue inﬂammation), citrullinated and MMP-degraded vimentin
(VICM) [20], osteocalcin (assessing bone formation), and C-terminal
telopeptide of type I collagen (CTX, indicating bone resorption). A
further aim was to investigate each biomarker’s predictive value for
early and late clinical response to the intervention and thus
potentially identify unique responder and non-responder proﬁles.Patients and methods
Study design and serum samples
The LITHE have previously been thoroughly described by
Kremer et al. [19] and Smolen et al. [18] (clinicalTrials.govidentiﬁer: NCT00106535). The study is a 2-year phase III, multi-
center, randomized, 3-arm, placebo-controlled, and parallel group
trial in patients with moderate to severely active RA who had an
inadequate response to MTX. The sub-study of LITHE consisted of
serum samples from a 1-year, double-blinded treatment study,
where 704 patients were randomized 1:1:1 to one of three
treatment groups: 4-mg/kg, 8-mg/kg TCZ, or placebo (PBO) in
combination with a stable dosage of MTX (10–25 mg/week). TCZ
and PBO were given intravenously over 4 weeks. The end point of
the biomarker sub-study was response rate, according to the
American college of rheumatology criteria, for 50% improvement
(ACR50).
Patients who failed to respond to treatment during the study,
that is, they experienced o20% improvement from baseline in the
swollen joint counts (SJC) and tender joint counts (TJC) at week 16
or later, they could receive blinded rescue therapy in a stepwise
fashion between weeks 16 and 28, as follows: in the ﬁrst-step
blinded rescue, patients receiving PBO þ MTX switched to TCZ
4 mg/kg þ MTX, patients receiving TCZ 4 mg/kg þ MTX switched
to TCZ 8 mg/kg þ MTX, and patients receiving TCZ 8 mg/kg þ
MTX remained on TCZ 8 mg/kg þ MTX. Second-step rescue
consisted of TCZ 8 mg/kg þ MTX for all patients, regardless of
initial treatment, and was offered through week 52, if inadequate
response persisted after three doses of ﬁrst-step rescue therapy.
Patients who did not respond after three doses of second-step
rescue discontinued treatment. Patients receiving rescue treat-
ment were designated as early non-responders (ERN) for the
purpose of the primary biomarker analyses.
In the study protocol, serum for biomarker research was
scheduled to be collected from patients who provided written
informed consent. Thus, the LITHE biomarker study was a pro-
spective study. Because the primary objective of the current
exploratory study was to examine the effect of IL-6R inhibition
with TCZ on biochemical marker levels, only patients who pro-
vided a baseline sample, before initiating therapy and at least one
post-dosing sample at 2, 4, 16, 24, and 52 weeks were included.
The blood was collected in the morning after an overnight fast of
48 h at baseline, weeks 4, 16, 24, and 52, while non-fasting blood
was collected at week 2. All samples were stored frozen at a
temperature below 701C until assayed.
The study was approved by the ethics committee at each
participating institution and was conducted according to the
Principles of Good Clinical Practice and according to the Declara-
tion of Helsinki. All patients provided written informed consent.
No steering committee was used for this study.
Biochemical marker assays
Serum levels of C2M [12], C3M [11], CRPM [14], and VICM [20]
were measured blindly by manual competitive ELISAs, developed
by Nordic Bioscience (Herlev, Denmark). Brieﬂy, for C2M, which
measures MMP-degraded type II collagen fragments; 4 ng/mL of
biotin-KPPGRDGAAG (American peptide, Sunnyvale, CA, USA) was
coated onto the streptavidin pre-coated 96-well plate (Roche
Diagnostics, Mannheim, Germany) and left for 30 min at 201C.
After washing (PBS þ 10% tween 20), the calibrators, controls, and
undiluted serum samples were added followed by peroxidase-
conjugated monoclonal antibody NB44-3C1, and incubated at 41C
overnight. The sample–antibody mix was washed off the well plate
and peroxidase reaction was visualized by 3,3′,5,5′-tetramethyl-
benzidine (TMB, Kem-En-tec, Taestrup, Denmark) at 201C and
stopped with sulfuric acid after 15 min. For C3M, which measures
the MMP-derived type III collagen neo-epitope, 96-well streptavi-
din-coated plates were coated with 0.4 ng/mL of KNGETGPQGP-
biotin and left for 30 min at 201C. After washing, calibrators,
controls, and serum samples (diluted 1:1 in incubation buffer)
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G12. The sample–antibody mix was incubated at 201C for 60 min.
TMB was added after washing off the plates and incubated at 201C
and stopped with sulfuric acid after 15 min. CRPM measurement
followed the same procedure as C3M; however, applying a differ-
ent peroxidase-conjugated antibody (NB94-1A7) and coater
(KAFVFPKESDK-biotin). For measurement of serum, VICM samples
were prediluted 4 times in incubation buffer. Streptavidin-coated
96-well plates were coated with 100 μL of 1-ng/mL biotin–
RLRSSVPGV–Citrulline and left for 30 min at 201C. After washing,
the calibrators, controls, and prediluted serum samples were
added followed by 100 μL of peroxidase-conjugated monoclonal
antibody NB212-1C5 and incubated at 41C overnight. After sample/
calibrator incubation, the wells were washed and incubated with
100 μL of TMB at 201C for 15 min, followed by the addition of 100-
μL stop solution (sulfuric acid) in each well. The colorimetric
reaction was measured at 450 nm with reference at 650 nm using
the Softmax Pros, version 5 software (Molecular Devices, Sunny-
vale, CA, USA). Intra- and inter-assay variations (CV) were below
8% and 10%, respectively, for all the above described assays.
Serum total MMP3 was measured by a two-site ELISA using two
polyclonal antibodies raised against human MMP3 (Quantikines,
R&D systems, Denmark). Intra- and inter-assay CVs were o10%.
Serum osteocalcin (OC) and CTX were measured by an automated
multiplex assay (IMPACT bone chip, Roche Diagnostics, Mannheim,
Germany) using the same antibodies as those employed in the
corresponding single-marker assays (Elecsys, Roche Diagnostics,
Mannheim, Germany) [21].
Statistical analyses
Summary statistics of general demographics, baseline RA char-
acteristics, and baseline ACR demographics (Table 1) included the
number of patients and the mean and standard deviation. The
primary analysis (Fig. 1) was based on the mean percentage
(7SEM) relative to the baseline measurement of the biochemical
markers separated into the treatment. Difference between the two
treatment groups, TCZ 4 mg/kg (TCZ4 þ MTX) and TCZ 8 mg/kg
(TCZ8 þ MTX), and placebo (placebo þ MTX) group was assessed by
one-way ANOVA at weeks 16 and 52 on log transformed data. The
p-values were adjusted for multiple comparisons by the Dunnett
test.
For markers showing signiﬁcant and consistent associations in
the primary analysis, further associations between change in
biomarker at week 4 and response at week 16 were investigatedTable 1
Summary of baseline demographics and disease activity in the biomarkers sub-study
Full trial average [18,19]
N 1190
Female (%) 83
Age, mean 7 SD years 52.0
Disease duration, mean 7 SD years 9.2
DAS28, mean 7 SD 6.5
Swollen joint count (SJC), mean 7 SD 17
Tender joint count (TJC), mean 7 SD 28
HAQ score, mean 7 SD 1.5
Total Genant-modiﬁed Sharp score (TGSS), mean 7 SD 28.7
ESR, mean 7 SD mm/h 46.3
CRP, mean 7 SD mg/dL 2.2
CRPM, mean 7 SD nmol/L
C2M, mean 7 SD nmol/L
C3M, mean 7 SD nmol/L
VICM, mean 7 SD nmol/L
MMP3, mean 7 SD mg/L
CTx, mean 7 SD ng/mL
Osteocalcin, mean 7 SD ng/mLusing a dichotomous approach in which patients were categorized
according to designation of “high” and “low” levels, and “respond-
ers” and “non-responders.” Sensitivity and speciﬁcity, including
AUCs, were used to determine the optimal cut-off values derived
from receiver–operator curve (ROC) analyses at highest likelihood
ratio. Odds ratios were calculated using these cut-off values.
Difference between responder and non-responder groups (Fig. 2)
was investigated by Student’s t-test.
All statistical analyses were performed using SAS software
version 9.1.3 and MedCalc version 12.3.0. Graphing was performed
using Prism Graphpad version 5.03.Results
Characteristics of the patient participating the LITHE sub-study
The full trial description is given by Kremer et al. [19]. The
LITHE study had approximately 400 patients in each treatment
arm, of which 82–84% were females with an average age of 52
years and mean disease duration of 9.2 years. The sub-study had
similar distribution of gender, age, and disease duration (Table 1).
There was no signiﬁcant difference between the disease activity
(DAS, SJC, TJC, and HAQ) and burden (TGSS) and between the full
trial and the biomarkers sub-population. Neither was there any
difference in the level of the acute-phase reactants, CRP, and ESR
(Table 1). There was no signiﬁcant difference in the biomarkers
baseline levels of the treatment groups (Table 1).
Efﬁcacy proﬁle; dose-dependent treatment effect on the serum
biomarker
Approximately 59% of the placebo–MTX, 40% of the TCZ4 þ
MTX, and 28% of the TCZ8 þ MTX patients were given rescue
treatment, as described in the Patients and methods section. The
following results show mean percentages of the baseline levels,
and the p-values are derived from comparisons with the placebo–
MTX group. Generally, the ﬁrst infusion of both TCZ4 and TCZ8
induced a peak reduction from baseline at week 2 in serum levels
of CRP, CRPM, C2M, C3M, and VICM and a peak increase in serum
CTx and OC (Fig. 1).
Serum CRP was suppressed completely by TCZ8þMTX (p o
0.0001), to 39% (p o 0.0001) by TCZ4 þ MTX and to 85% by
placebo þ MTX at week 16 (Fig. 1A). Serum CRPM, reﬂecting
MMP-degraded CRP, was signiﬁcantly (p o 0.0001) reduced toPBO þ MTX TCZ4 þ MTX TCZ8 þ MTX
255 241 244
83 86 80
51.6 7 12.6 52.3 7 13.1 53.8 7 10.9
9.3 7 8.2 10.3 7 8.3 9.9 7 8.7
6.5 7 1.0 6.5 7 0.9 6.5 7 0.9
16 7 9 17 7 10 16 7 9
28 7 16 27 7 14 28 7 15
1.5 7 0.6 1.5 7 0.7 1.5 7 0.6
27.9 7 32.3 28.4 7 28.5 28.2 7 29.9
46.5 7 23.3 44.6 7 23.4 44.2 7 22.5
2.2 7 2.5 2.0 7 2.4 2.2 7 2.6
17.7 7 9.4 16.6 7 7.1 16.9 7 8.8
0.56 7 0.20 0.55 7 0.17 0.55 7 0.20
45.2 7 23.4 43.8 7 25.4 40.5 7 17.9
10.4 7 16.2 16.1 7 50.5 20.7 7 72.8
50.9 7 50.1 48.3 7 43.4 64.1 7 81.0
0.43 7 0.20 0.40 7 0.19 0.41 7 0.21
22.1 7 14.2 21.8 7 13.5 21.2 7 13.2
Fig. 1. Dose-dependent treatment biomarker proﬁles. Serum biomarkers were measured at baseline, 2, 4, 16, 24, and 52 weeks in the three treatment groups. (A) Normal
serum CRP; (B) serum CRPM and CRP degraded by proteases; (C) serum C2M and cartilage degradation; (D) serum C3M and synovial turnover; (E) serum VICM, and
citrullinated- and proteases-degraded vimentin; (F) serum MMP3 and circulating levels of MMP3; (G) serum CTx and bone resorption; and (H) serum OC and bone
formation. The horizontal line gives the baseline level, and the vertical line gives the time of rescue treatment. The level of the biomarkers and the number of patients in each
treatment group is indicated for week 16 (prior to rescue) and week 52 (end point). Data are shown as mean 7SEM bars and signiﬁcance levels as * for p o 0.05 and # for
p o 0.001.
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89% and placebo þ MTX to 96%; however, there was no signiﬁcant
difference between the two TCZ-treated groups and the placebo
group (Fig. 1B). After the escape point at week 16, serum CRPM
continued to fall in all three groups reaching 88%, 84%, and 63% of
baseline levels at week 52 (Fig. 1B). Thus, there was no difference
between the TCZ4 þ MTX- and placebo þ MTX-treated groups.
Serum C2M, which reﬂects cartilage degradation, was reduced to
93% of baseline levels by placebo þ MTX, 92% by TCZ4 þ MTX, and86% (p o 0.01) by TCZ8 þ MTX at week 16 (Fig. 1C). After the
escape point, the level of C2M dropped an additional 2% in the
TCZ8 þ MTX group at week 52. Thus, TCZ4 did not prevent release
of C2M any more than placebo þ MTX. Serum C3M, reﬂecting
synovial turnover, displayed a similar pattern as serum C2M.
Serum C3M was reduced to 97% of baseline levels by placebo þ
MTX, to 87% by TCZ4 þ MTX, and to 71% (p o 0.0001) for TCZ8 at
week 16 (Fig. 1D). TCZ8 þ MTX induced a further decrease in C3M,
reaching 68% of baseline levels at week 52, whereas the slightly
Fig. 2. The difference in biomarker levels at week 4 between early responders (ER, white bars) and early non-responders (ENR, black bars) after the ﬁrst doses of TCZ8 þ
MTX. (A) Normal serum CRP; (B) serum CRPM and CRP degraded by proteases; (C) serum C2M, indicating cartilage degradation; and (D) serum C3M, indicating synovial
turnover. Data are shown as the change from baseline giving the mean with SEM error bars. Signiﬁcance levels at p o 0.05 and p o 0.01 are shown.
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tained. It reached 92% at week 52, which was a similar outcome for
the placebo þ MTX group (Fig. 1D)
Serum VICM, which measures the release of citrullinated
vimentin fragments, was reduced to approximately 47% of baseline
(p o 0.0001) by TCZ8 þ MTX at week 16, whereas TCZ4 þ MTX
and placebo þ MTX showed similar patterns to each other reach-
ing 94% and 97% of baseline levels (Fig. 1E). Mean serum VICM
dropped further in the TCZ8 þ MTX group to 43% of baseline at
week 52, but it increased in the TCZ4 þ MTX group. However, the
variation in VICM levels between patients on TCZ4 þ MTX
increased markedly at the end of the year, being 86% in the
placebo þ MTX group at week 52.
TCZ4 þ MTX and TCZ8 þ MTX were able to reduce the serum
MMP3 to 66% and 56% at week 16 and to 55% and 44% at week 52,
respectively. Placebo þ MTX had no marked effect on MMP3 levels
(Fig. 1F).
Serum CTx, a measure of bone resorption, was increased by
TCZ8 þ MTX, but only signiﬁcantly (p o 0.05) at week 24
compared with placebo þ MTX. TCZ4 þ MTX and placebo þ
MTX showed a slight reduction from baseline levels (Fig. 1G). Bone
formation, measured by serum OC, was signiﬁcantly increased by
TCZ4 þ MTX to 112% (p o 0.001) and 109% (ns) and by TCZ8 þ
MTX to 117% (p o 0.0001) and 122% (p o 0.0001) at weeks 16 and
52, respectively, whereas placebo þ MTX reduced the level of
serum OC to 95% of baseline at both time points (Fig. 1H).
Odds ratio for early response to TCZ þ MTX
Patients, who did not achieve a 20% reduction in SJC and TJC at
week 16 and were given rescue therapy, were designated as earlyTable 2
Odds ratios for early response to treatment measured by the change in the biomarkers
All PL
CRP OR (95%CI) 2.5 (1.8–3.4) 1.8
p Value o0.0001 0.0
Cut-off (%) 62.7 15
AUC 0.62 (0.58–0.65) 0.5
CRPM OR (95%CI) 2.1 (1.4–3.0) 2.2
P value 0.0001 0.0
Cut-off (%) 101 111
AUC 0.59 (0.55–0.63) 0.5
C2M OR (95%CI) 1.9 (1.3–2.7) 1.4
p Value 0.0012 0.2
Cut-off (%) 92.6 88
AUC 0.58 (0.54–0.62) 0.5
C3M OR (95%CI) 6.2 (3.3–11) 1.7
P value o0.0001 0.7
Cut-off (%) 71.2 10
AUC 0.60 (0.56–0.64) 0.5non-responders (ENR). The remaining patients were designated as
early responders (ER).
The optimal biomarker cut-offs, determined by ROCs for the
study population as a whole and for each individual treatment
arm, are shown in Table 2. The change in CRP at week 4 was
signiﬁcantly predictive of response to treatment (OR 2.5, p o
0.0001). Change in CRP level was not predictive of response to
placebo þ MTX (OR 1.8, ns). Changes in CRP had some predictive
value in the TCZ4 þ MTX group (OR 2.2, p o 0.05), but not in
the TCZ8 þ MTX group (Table 2). The cut-off for optimal CRP
levels in the TCZ8 þ MTX group was approximately 92%
(Fig. 2A), showing that both ER and ENR patients had sup-
pressed CRP levels. The change in CRPM was predictive of a
general response (OR 2.1, p o 0.001). The change was of
borderline signiﬁcance (p o 0.05) for the response to TCZ4 þ
MTX. The change in serum C2M as an effect of TCZ8 þ MTX had
an OR of 5.8 (p o 0.001) for predicting response, whereas no
such thing was seen in the two other treatment arms. A change
in C3M was strongly predictive of early improvement to TCZ8 þ
MTX with an OR of 9.6 (p o 0.001). Thus, CRPM, C2M, and C3M
were the only three markers of the tested panel that were
predictive of early response and then, only to TCZ8 þ MTX
treatment. The levels of these three biomarkers and CRP in the
TCZ8þMTX group are shown in Fig. 2. The level of serum CRP
was inhibited to the same extent in both ENRs and ERs (Fig. 2A).
Serum CRPM was suppressed by TCZ8 þ MTX by 30% for the ER
group and by 16% for the ENR group—a difference that was
signiﬁcantly different (p o 0.05). Serum C2M was reduced by
12% in the TCZ8 þ MTX ER group, whereas the level was slightly
increased in ENR (Fig. 2C). Serum C3M was signiﬁcantly sup-
pressed in the responder group compared to the ENR (Fig. 2D).from baseline to week 4
ACEBO þ MTX TCZ4 þ MTX TCZ8 þ MTX
(1.0–3.3) 2.2 (1.3–4.2) 1.6 (0.8–3.1)
59 0.02 0.18
5 62.4 7.89
0 (0.45–0.55) 0.58 (0.51–0.64) 0.55 (0.48–0.61)
(1.1–4.1) 2.0 (1.0–43.9) 3.5 (1.5–8.0)
20 0.047 0.004
101 88.9
1 (0.44–0.58) 0.53 (0.46–0.61) 0.64 (0.56–0.71)
(0.7–2.7) 1.8 (0.9–3.5) 5.8 (2.2–15)
9 0.11 0.0003
.2 106 92.6
1 (0.44–0.58) 0.53 (0.46–0.60) 0.69 (0.61–0.75)
(0.9–3.0) 2.5 (0.8–7.5) 8.1 (2.3–28)
5 0.11 0.001
0 127 71.6
4 (0.47–0.62) 0.52 (0.45–0.59) 0.68 (0.60–0.75)
Fig. 3. The biomarker proﬁle of patients classiﬁed as ACR50 responders (black squares), non-responders (open circles), or the ENR (gray triangles) from baseline to week 52.
(A) Serum CRP levels in response to TCZ8. (B) Serum CRPM levels in response to TCZ8. (C) Serum C2M levels in response to TCZ8. (D) Serum C3M levels in response to TCZ8.
(E) Serum CRP levels in response to TCZ4. (F) CRPM levels in response to TCZ4. (G) Serum C2M levels in response to TCZ4. (H) Serum C3M levels in response to TCZ4. Data are
shown as mean with SEMs.
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An analysis of ENRs, and the 52-week ACR50 responders
(ACR50R) and non-responders (ACR50NR), showed that serum
level of CRP was completely inhibited by TCZ8 þ MTX in all threegroups (Fig. 3A). Serum CRPMwas decreased in response to TCZ8 þ
MTX in the ACR50R and the ACR50NR groups to approximately
74% and 72% at week 4, and to 71% and 68% at week 24 (Fig. 3B).
Serum CRPM levels also decreased in the ENR group, but not to the
same extent as in the other groups. After the ﬁrst-step rescue
treatment was administered to the ENR group at week 16, the level
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The cartilage degradation marker, C2M, and synovial turnover
marker, C3M, were initially inhibited by TCZ8 þ MTX to a greater
extent in the ACR50R group than in the ACR50NR group (Fig. 3C
and D). The ENR group displayed a markedly different proﬁle to
the other two groups (Fig. 3C and D). C3M levels decreased
markedly after ﬁrst-step rescue treatment.
Serum CRP levels were inhibited the most in the ACR50R group
receiving TCZ4 þ MTX. However, the between-patient variation
was large, indicating that some patients had signiﬁcantly inhibited
levels while others did not. The two non-responder groups
followed a similar pattern to each other (Fig. 3E). CRPM was
signiﬁcantly inhibited in the ACR50R group compared to the
ACR50NR (Fig. 3F). The level of CRPM slightly decreased in a
similar fashion in the ENR and ACR50NR until the ﬁrst-step rescue
point, after which the level decreased further in the ENR group
(Fig. 3F). Serum C2M was signiﬁcantly lower in the ACR50R than in
the two non-responders groups prior to the ﬁrst rescue point
(Fig. 3G). There was no signiﬁcant difference in the level of serum
C3M in either non-responder group (Fig. 3H), although the
ACR50NR group seemed to have a less inhibited level of C3M.Discussion
This 1-year sub-study of the LITHE trial investigated eight
biomarkers of joint destruction and inﬂammation. The novel
biomarkers are all neo-epitopes released during tissue processing,
and so are measures of pathological events in inﬂamed tissue [22].
We investigated the biomarker proﬁle in response to 4- or 8-mg/kg
TCZ treatment, or placebo, combined with MTX. We demonstrated
that there was a signiﬁcant difference between the two active
doses and the placebo group for speciﬁc markers of tissue
inﬂammation and cartilage turnover. Intact CRP levels were
inhibited by both doses of TCZ, as expected, whereas cartilage
degradation, as measured by C2M, and synovial inﬂammation, as
measured by serum CRPM and C3M, were only signiﬁcantly
inhibited by TCZ8 þ MTX. These results indicate that TCZ4 þ
MTX indeed had anti-inﬂammatory activity on the systemic level,
but this did not convert into a protective effect on joint tissue. Our
analysis of the ability of these biomarkers to discriminate between
early responders and non-responders showed that patients with a
signiﬁcant decrease in serum levels of CRPM, C2M, and C3M, but
not intact CRP, had a signiﬁcantly higher OR for response to TCZ8 þ
MTX, but not to TCZ4 þ MTX. These results indicate that the
individual biomarkers may possess predictive properties for TCZ
response. Lastly, we found that the dose-dependent proﬁles of
these markers were signiﬁcantly different between ACR50 res-
ponders and non-responders, as well as early non-responders
(escape patients). These last results suggest that the neo-epitope
biomarkers can be used to identify responders and non-
responders at an early time point
The biomarkers were time-dependently attenuated by the TCZ
administration, which may suggest a continued clinical beneﬁt of
the intervention. In particular, the CRPM marker, in contrast to
traditional CRP, showed time-dependent resolution. CRP, which is
one of the main clinical targets of anti-IL6R treatment, is produced
in the liver in response to increased levels of IL-6 [15,23,24]. TCZ8
completely inhibited the level of CRP, while TCZ4 only inhibited
the level of CRP by 50%. The limited effect of MTX on CRP levels in
the current study compared with previous studies [25] was
somewhat predictive of MTX response, with an OR of 6.5 and an
optimal cut-off of 55%. Patients who maintained their CRP at less
than 55% of baseline were likely to be early responders. However,
CRP did not predict clinical response to TCZ. In contrast, serum
CRPM was actually predictive of clinical response to TCZ. The ORsfor prediction of early clinical response to TCZ8 and TCZ4 were
4 and 2, respectively. Interestingly, the separation between ACR50
responders and non-responders to TCZ8 became more pro-
nounced over time. An explanation for this could be that as CRP
production was inhibited by anti-IL-6 treatment, the deposition of
CRP in the inﬂamed tissue was attenuated and consequently the
cleavage of it was likewise inhibited after a time lag. This is
illustrated in the differences in the proﬁles of CRP and CRPM in
responders and non-responders. While CRP was completely
inhibited by TCZ8 in ACR50 responders and non-responders, the
decrease in CRPM levels was signiﬁcantly greater in the ACR50
responder group than non-responders. The continued decrease in
CRPM over the year may have been the result of previously
deposited CRP being slowly released and the joint is rebalancing
toward a healthier phenotype.
Cartilage degradation and synovial turnover, measured by
serum C2M and C3M, were decreased by TCZ8, but not by TCZ4.
This suggests a marked difference in the physiological response to
the two doses. Changes in serum VICM showed the similar dose–
time proﬁle. MMP3, which is believed to be one of the MMPs
involved in tissue degradation, was lowered to the same extent for
both doses of TCZ. MMP3 is however not the only MMP involved
in joint tissue degradation [26]. Several MMPs have been found to
be up-regulated in RA [27,28], many of which are directly
regulated by IL-6 and CRP [24,29]. This may be one explanation
to why there is a disconnection between the change in the MMP-
derived tissue biomarkers (i.e., C2M, C3M, VICM, and CRPM) and
MMP3. TCZ þ MTX induced a rapid and dose-dependent reduction
in MMP3 with a signiﬁcantly larger reduction with the 8-mg/kg
dose. This result suggests that TCZ 8 mg/kg in combination with
MTX is more effective than the 4-mg/kg dose in decreasing
cartilage turnover and degradation, and that TCZ limits joint tissue
inﬂammation.
Our results conﬁrm a similar biomarker analysis performed for
the RADIATE study, examining the effects of TCZ on bone and
inﬂammation [16]. TCZ added to MTX induced a modest, but
signiﬁcant and dose-dependent increase in the systemic bone
formation marker in the RADIATE analysis [16], as it did in the
current study, with maintenance of bone resorption. These results
provide evidence that TCZ, especially at the dose of 8 mg/kg, has a
positive effect on bone balance, which in untreated patients
[22,30–32] is imbalanced, leading to continued bone loss. This
notion was supported by Terpos et al. [33], who observed a
disruption of the bone balance with 8-mg/kg TCZ by measurement
of bone remodeling markers of the wnt pathway. Although the
consequence of the effect of TCZ on bone mineral density and
fragility fracture is difﬁcult to predict, the magnitude of the
observed changes is greater than the physiological within-
patient variability and is similar to those observed with strontium
ranelate, an effective therapy in postmenopausal osteoporosis
[34,35]. The effect of IL-6 receptor inhibition on bone remodeling
in humans should be further examined.
The ACR50 non-responders in the TCZ4 group might have had
an initial inhibition of joint inﬂammation, providing initial and
sufﬁcient clinical beneﬁt to avoid the ACR50 non-responders from
being given rescue treatment. An important question is whether
they would have beneﬁted from dose-escalation. The patients
treated with TCZ4, who did not respond to treatment at week 16
(and were thus deemed as escape patients), were escalated to
TCZ8. Serum CRP levels for these patients (ENR) were similar to
those of the ACR50 non-responder group. However, the level of
CRPM dropped markedly after escalation of the dose. A similar
pattern was observed in markers of cartilage degradation: the level
of C2M dropped to the level of the ACR50R group after escalating
the dose, and continued to drop after the second rescue point.
Serum levels of C3M were likewise markedly reduced by the
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not pass the second escape point evaluation left the study. Thus,
the patients remaining in the escape group were patients who had
some level of clinical response. These results indicate that a subset
of patients actually beneﬁted from increased dose of TCZ and that
the applied biomarkers probably could assist in the identiﬁcation
of patients who would beneﬁt from an up-scaled dose.
The main limitation of the study is that radiographic evidence
showed only a very low rate of progression, especially in the TCZ
treatment groups, which impaired the power to detect signiﬁcant
associations and created large conﬁdence intervals for the odds
ratios. Baseline correlations between the biomarkers and clinical
characteristics were performed; however, it would be of signiﬁcant
interest to investigate whether these same markers would be
prognostic of disease progression.
We have in this study measured serum levels of end products of
tissue destruction, which clearly provide additional value than
measurement of individual proteases and cytokines regulating
tissue destruction. RA is heavily regulated and driven by pro-
inﬂammatory cytokines, such as IL-1, IL-6, IL-17, and TNFα. Meas-
urement of the level of these cytokines as predictive markers has
yet to be supported. While the variation in the levels of the
individual cytokines and consequent signaling pathways may be
large, the common end products are tissue destruction by cleavage
of joint-speciﬁc proteins mediated by the increase in the proteases
[4]. Such biomarkers measure the burden of disease by, for
example, indicating how much cartilage is being lost, and the
efﬁcacy of the intervention directly on the tissue in question. The
same biomarkers are being investigated in other rheumatic dis-
eases, such as osteoarthritis (OA) and ankylosing spondylitis (AS).
In OA, serum and urinary levels of cartilage products were
correlated with JSN [6,36–39]. In AS, both biomarkers of cartilage
and synovial turnover were increased in patients with a high
burden of disease as compared to patients with low burden and
controls [12,40].Conclusion
In conclusion, we have identiﬁed biomarkers that indicate
responders to treatment and that reﬂect joint deterioration and
inﬂammation. These markers are closely associated with the
pathology of the joints, and may thus be considered as more true
biomarkers of efﬁcacy, and thus better tools for monitoring and
understanding drug efﬁcacy and mode of actions, than standard
markers. The marker panel we identiﬁed may be useful for
identifying the patients who would beneﬁt the most from TCZ
treatment and those who would beneﬁt from escalating the dose
from 4 to 8 mg/kg. Whether these proﬁles are transferrable to
other indications or interventions needs to be tested further.Competing interests
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